<DOC>
	<DOCNO>NCT01609153</DOCNO>
	<brief_summary>A study examine whether antipsychotic combination treatment olanzapine amisulpride effective olanzapine amisulpride alone .</brief_summary>
	<brief_title>Comparison Antipsychotic Combination Treatment Olanzapine Amisulpride Monotherapy</brief_title>
	<detailed_description>Polypharmacy antipsychotic therapy important issue treat patient schizophrenia . It well confirm combination two antipsychotic drug lead therapeutic benefit contrast monotherapy . However highly frequent practice combine atypical non-clozapine treatment could due potential benefit seek alternative high rate non-response acute phase . Therefore need trial sufficient power address efficacy safety issue regimen . Combining two selected atypical drug complementary way may minimize side-effects enhance efficacy . In order specify advantage intend examine approach combination treatment : Amisulpride olanzapine show complement receptor bind profile show efficacy good tolerability administer combination retrospective study . The object trial study whether acutely ill patient combination amisulpride olanzapine frequently symptomatic remission 8 week olanzapine amisulpride monotherapy .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Sultopride</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<criteria>Patients schizophrenia schizoaffective disorder accord International Classification Diseases ( ICD10 ) ; age 1865 ; Positive Negative Symptom Scale TotalScore ≥ 70 two item positive symptom subscale ≥4 . voluntary treatment write informed consent legal capacity exclusion pregnancy laboratory test ( Beta HCG ) participation interventional study drug medical device first episode patient physical disease might effect conduct evaluation trial contraindication medication accord expert information oversensitivity active substance component drug use know clozapine resistance suicidal ideation pregnancy lactation pregnancy absence save contraception dependency sponsor investigator institutionalization judicial regulatory order oversensitivity placebo ( mannite/aerosil )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>amisulpride</keyword>
	<keyword>olanzapine</keyword>
	<keyword>polypharmacy</keyword>
</DOC>